94 related articles for article (PubMed ID: 23777919)
41. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
Aesoy R; Sanchez BC; Norum JH; Lewensohn R; Viktorsson K; Linderholm B
Mol Cancer Res; 2008 Oct; 6(10):1630-8. PubMed ID: 18922978
[TBL] [Abstract][Full Text] [Related]
42. Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen.
Reddel RR; Murphy LC; Hall RE; Sutherland RL
Cancer Res; 1985 Apr; 45(4):1525-31. PubMed ID: 3978620
[TBL] [Abstract][Full Text] [Related]
43. Innovative drug delivery nanosystems improve the anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma.
Maillard S; Ameller T; Gauduchon J; Gougelet A; Gouilleux F; Legrand P; Marsaud V; Fattal E; Sola B; Renoir JM
J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):111-21. PubMed ID: 15862956
[TBL] [Abstract][Full Text] [Related]
44. Substituted Tetrahydroisoquinolines as Microtubule-destabilizing Agents in Triple Negative Human Breast Cancer Cells.
Gangapuram M; Jean R; Mazzio E; Badisa R; Eyunni S; Goodman CB; Redda KK; Soliman KF
Anticancer Res; 2016 Oct; 36(10):5043-5052. PubMed ID: 27798863
[TBL] [Abstract][Full Text] [Related]
45. Inhibitory effects of ginseng sapogenins on the proliferation of triple negative breast cancer MDA-MB-231 cells.
Kwak JH; Park JY; Lee D; Kwak JY; Park EH; Kim KH; Park HJ; Kim HY; Jang HJ; Ham J; Hwang GS; Yamabe N; Kang KS
Bioorg Med Chem Lett; 2014 Dec; 24(23):5409-12. PubMed ID: 25453798
[TBL] [Abstract][Full Text] [Related]
46. Curcumin-derivative nanomicelles for the treatment of triple negative breast cancer.
Taurin S; Nehoff H; Diong J; Larsen L; Rosengren RJ; Greish K
J Drug Target; 2013 Aug; 21(7):675-83. PubMed ID: 23679865
[TBL] [Abstract][Full Text] [Related]
47. Cellular uptake, cytotoxicity and in-vivo evaluation of Tamoxifen citrate loaded niosomes.
Shaker DS; Shaker MA; Hanafy MS
Int J Pharm; 2015 Sep; 493(1-2):285-94. PubMed ID: 26200748
[TBL] [Abstract][Full Text] [Related]
48. Targeted Lipid Nanoemulsions Encapsulating Epigenetic Drugs Exhibit Selective Cytotoxicity on CDH1
Kim B; Pena CD; Auguste DT
Mol Pharm; 2019 May; 16(5):1813-1826. PubMed ID: 30883132
[TBL] [Abstract][Full Text] [Related]
49. Physicochemical Characterization of Ferrocifen Lipid Nanocapsules: Customized Drug Delivery Systems Guided by the Molecular Structure.
Idlas P; Lepeltier E; Bastiat G; Pigeon P; McGlinchey MJ; Lautram N; Vessières A; Jaouen G; Passirani C
Langmuir; 2023 Feb; 39(5):1885-1896. PubMed ID: 36693216
[TBL] [Abstract][Full Text] [Related]
50. The length of the bridging chain in ansa-metallocenes influences their antiproliferative activity against triple negative breast cancer cells (TNBC).
Beauperin M; Top S; Richard MA; Plażuk D; Pigeon P; Toma S; Poláčková V; Jaouen G
Dalton Trans; 2016 Aug; 45(33):13126-34. PubMed ID: 27276499
[TBL] [Abstract][Full Text] [Related]
51. Nanomedicine for the treatment of triple-negative breast cancer.
Kutty RV; Wei Leong DT; Feng SS
Nanomedicine (Lond); 2014 Apr; 9(5):561-4. PubMed ID: 24827837
[No Abstract] [Full Text] [Related]
52. In Vivo Performance of a Ruthenium-cyclopentadienyl Compound in an Orthotopic Triple Negative Breast Cancer Model.
Mendes N; Tortosa F; Valente A; Marques F; Matos A; Morais TS; Tomaz AI; Gärtner F; Garcia MH
Anticancer Agents Med Chem; 2017; 17(1):126-136. PubMed ID: 27671310
[TBL] [Abstract][Full Text] [Related]
53. Organometallic Antitumor Compounds: Ferrocifens as Precursors to Quinone Methides.
Wang Y; Pigeon P; Top S; McGlinchey MJ; Jaouen G
Angew Chem Int Ed Engl; 2015 Aug; 54(35):10230-3. PubMed ID: 26179051
[TBL] [Abstract][Full Text] [Related]
54. Tretinoin-loaded lipid-core nanocapsules overcome the triple-negative breast cancer cell resistance to tretinoin and show synergistic effect on cytotoxicity induced by doxorubicin and 5-fluororacil.
Schultze E; Buss J; Coradini K; Begnini KR; Guterres SS; Collares T; Beck RCR; Pohlmann AR; Seixas FK
Biomed Pharmacother; 2017 Dec; 96():404-409. PubMed ID: 29031198
[TBL] [Abstract][Full Text] [Related]
55. Biological response and cytotoxicity induced by lipid nanocapsules.
Szwed M; Torgersen ML; Kumari RV; Yadava SK; Pust S; Iversen TG; Skotland T; Giri J; Sandvig K
J Nanobiotechnology; 2020 Jan; 18(1):5. PubMed ID: 31907052
[TBL] [Abstract][Full Text] [Related]
56. Folic acid-doxorubicin polymeric nanocapsules: A promising formulation for the treatment of triple-negative breast cancer.
Cé R; Couto GK; Pacheco BZ; Dallemole DR; Paschoal JD; Pacheco BS; Guterres SS; Seixas F; Collares T; Pohlmann AR
Eur J Pharm Sci; 2021 Oct; 165():105943. PubMed ID: 34260893
[TBL] [Abstract][Full Text] [Related]
57. Theranostic multimodular potential of zinc-doped ferrite-saturated metal-binding protein-loaded novel nanocapsules in cancers.
Kamalapuram SK; Kanwar RK; Roy K; Chaudhary R; Sehgal R; Kanwar JR
Int J Nanomedicine; 2016; 11():1349-66. PubMed ID: 27099495
[TBL] [Abstract][Full Text] [Related]
58. Switching indication of PEGylated lipid nanocapsules-loaded with rolapitant and deferasirox against breast cancer: Enhanced in-vitro and in-vivo cytotoxicity.
Kabil MF; Mahmoud MY; Bakr AF; Zaafar D; El-Sherbiny IM
Life Sci; 2022 Sep; 305():120731. PubMed ID: 35753435
[TBL] [Abstract][Full Text] [Related]
59.
Maity S; Tomar MS; Wasnik K; Patra S; Modak MD; Gupta PS; Pareek D; Singh M; Paik P
ACS Biomater Sci Eng; 2022 Aug; 8(8):3608-3622. PubMed ID: 35892286
[TBL] [Abstract][Full Text] [Related]
60. Accounting for quiescent cells in tumour growth and cancer treatment.
Florian JA; Eiseman JL; Parker RS
Syst Biol (Stevenage); 2005 Dec; 152(4):185-92. PubMed ID: 16986259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
